Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy

• DOI: 10.1371/journal.pone.0234191
• Publication Date: 2020-06-24T17:35:10Z
• Authors: Anne-Sophie Hamy; Lauren Darrigues; Enora Laas; Diane De Croze; Lucian Topciu; Giang-Thanh Lam; Clemence Evrevin; Sonia Rozette; Lucie Laot; Florence Lerebours; Jean-Yves Pierga; Marie Osdoit; Matthieu Faron; Jean-Guillaume Feron; Marick Laé; Fabien Reyal
• Keywords: Triple-negative breast cancer

Introduction The Residual Cancer Burden (RCB) quantifies residual disease after neoadjuvant chemotherapy (NAC). Its predictive value has not been validated on large cohorts with long-term follow up. objective of this work is to independently evaluate the prognostic RCB index depending BC subtypes (Luminal, HER2-positive and triple negative (TNBCs)). Methods We retrospectively evaluated surgical specimens from a cohort T1-T3NxM0 patients treated NAC between 2002 2012. analyzed association relapse-free survival (RFS), overall (OS) among global population, stratification by subtypes. Results 717 were included (luminal (n = 222, 31%), TNBC 319, 44.5%), 176, 24.5%)). After median follow-up 99.9 months, was significantly associated RFS. RCB-0 displayed similar prognosis when compared RCB-I group, while RCB-II RCB-III classes at increased risk relapse (RCB-II versus RCB-0: HR 3.25 CI [2.1–5.1] p<0.001; 5.6 [3.5–8.9] p<0.001). impact significant for cancers; but luminal cancers (Pinteraction 0.07). poor (8-years RFS: 52.7%, 95% [44.8–62.0]) particularly in subgroup, where RFS 12.7 months. Conclusion reliable score. accurately identifies high recurrence (RCB-III) or who must be offered second-line adjuvant therapies.